Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> L-Ascorbic acid [50-81-7]

L-Ascorbic acid [50-81-7]

Imprimer Imprimer
Identifiez-vous

Référence HY-B0166-1g

Conditionnement : 1g

Marque : MedChemExpress

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Description

L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor[1][2][3]. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells[4].

IC50 & Target

T-type calcium channel

 

Microbial Metabolite

 

Cellular Effect
Cell Line Type Value Description References
A549 IC50
>100 μM
Compound: L-ASA
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31586832]
CFPAC-1 IC50
>100 μM
Compound: L-ASA
Antiproliferative activity against human CFPAC-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human CFPAC-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31586832]
Erythrocyte EC50
119.87 μg/mL
Compound: Ascorbic acid
Antioxidant activity in erythrocytes assessed as inhibition of hemolysis
Antioxidant activity in erythrocytes assessed as inhibition of hemolysis
[PMID: 22677320]
Erythrocyte EC50
96.625 μg/mL
Compound: Ascorbic acid
Hemolysis of human erythrocytes after 30 mins by spectrophotometry
Hemolysis of human erythrocytes after 30 mins by spectrophotometry
[PMID: 23811092]
HCT-116 IC50
>100 μM
Compound: L-ASA
Antiproliferative activity against human HCT116cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT116cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31586832]
HEK293 EC50
0.5 nM
Compound: Ascorbic acid
Agonist activity at human adrenergic alpha2B receptor expressed in HEK293 cells coexpressing Gqi5 protein by FLIPR assay
Agonist activity at human adrenergic alpha2B receptor expressed in HEK293 cells coexpressing Gqi5 protein by FLIPR assay
[PMID: 19243956]
HEK293 EC50
156 μM
Compound: 54670067
Substrate uptake and inhibition of the Na(+)/L-Ascorbic Acid Transporter 1 (SVCT1, SLC23A1) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 JumpIN-SLC23A1 cells (PubChem AID: 1794810)
Substrate uptake and inhibition of the Na(+)/L-Ascorbic Acid Transporter 1 (SVCT1, SLC23A1) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 JumpIN-SLC23A1 cells (PubChem AID: 1794810)
10.5281/zenodo.7360349
HeLa IC50
>100 μM
Compound: L-ASA
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31586832]
HepG2 IC50
>100 μM
Compound: L-ASA
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31586832]
HFF IC50
>100 μM
Compound: L-ASA
Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31586832]
HL-60 IC50
0.01 μM
Compound: Vitamin C
Antioxidant activity in human HL60 cells assessed as inhibition of relative oxygen species generation by DCFH-DA method
Antioxidant activity in human HL60 cells assessed as inhibition of relative oxygen species generation by DCFH-DA method
[PMID: 19555121]
HL-60 IC50
10.2 μM
Compound: Vitamin C
Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay
Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay
[PMID: 16562834]
HL-60 IC50
9.7 μM
Compound: Vitamin C
Antioxidant activity against TPA-induced ROS production in human HL60 cells by 2',7'-dichlorodihydrofluorescein diacetate cellular-based assay
Antioxidant activity against TPA-induced ROS production in human HL60 cells by 2',7'-dichlorodihydrofluorescein diacetate cellular-based assay
[PMID: 12762791]
J774.A1 IC50
>100 μM
Compound: AA
Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based analysis
Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based analysis
[PMID: 33422907]
MCF7 IC50
>100 μM
Compound: L-ASA
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31586832]
RD EC50
>2270 μM
Compound: AA
Antiviral activity against Herpes simplex virus type 1 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against Herpes simplex virus type 1 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect
[PMID: 22390834]
SW-620 IC50
>100 μM
Compound: L-ASA
Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31586832]
In Vitro

The anti-cancer effects of L-Ascorbic acid are determined by sodium-dependent vitamin C transporter 2 (SVCT-2), a transporter of L-ascorbic acid. L-Ascorbic acid (0.1 μM-2 mM) exhibits anti-cancer effects according to SVCT-2 expression and L-ascorbic acid uptake. Human colorectal cancer cell lines displays differential responses to L-ascorbic acid, primarily depending on the expression level of SVCT-2[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

L-Ascorbic acid Related Antibodies

Cell Viability Assay[4]

Cell Line: High SVCT-2 expressing cell lines Sw620, Sw480, LoVo, SNU-C4; Low SVCT-2 expressing cell lines HCT15, HCT116, DLD-1, CoLo-205
Concentration: 0, 0.1 μM, 1 μM, 10 μM, 0.1 mM, 0.5 mM, 1 mM, and 2 mM
Incubation Time: 24 hours
Result: Some high SVCT-2 expressing cancer cells demonstrated a dramatic cell-autonomous inhibitory effect of L-ascorbic acid.
Low SVCT-2 expressing cell lines showed biphasic responses to L-ascorbic acid.

Western Blot Analysis[4]

Cell Line: Sw620, Sw480, LoVo, SNU-C4, HCT15, HCT116, DLD-1, CoLo-205 cell lines
Concentration: 1 mM
Incubation Time:
Result: The cell lines showed different levels of SVCT-2 expression in western blot analyses: Sw620, Sw480, and Lovo expressed high levels of SVCT-2 whereas HCT116, HCT15, and DLD-1 expressed low levels.
In Vivo

L-Ascorbic acid/Tolbutamide produces hypoglycaemic activity in a dose dependant manner in normal (60 mg/kg) and diabetic (40 mg/kg) condition. In the presence of L-ascorbic acid, Tolbuatmide (20 mg/kg) produces early onset of action and maintained for longer period compared to Tolbutamide matching control[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Normal rats:Albino rats of either sex weighing between 125-175 g[5]
Dosage: Group I received L-ascorbic acid 60 mg/kg, Group II received Tolbutamide 20 mg/kg and Group III was given L-ascorbic acid (60 mg/kg) prior to the administration of tolbutamide 20 mg/kg
Administration: Administered orally
Result: L-ascorbic acid at the dose of 60 mg/kg produced 50.91% blood glucose reduction at 0.5 h and 20 mg/kg body weight of Tolbutamide produced 33% at 4 h as peak effects. In the presence of L-ascorbic acid (60 mg/kg), the action of Tolbutamide was early in onset and maintained for 6 h.
Animal Model: Diabetic rats:Albino rats of either sex weighing between 125 to 175 g were fasted overnight before injection with Alloxan[5]
Dosage: Group I received L-ascorbic acid 40 mg/kg and Group II received Tolbutamide 20 mg/kg while Group III was given L-ascorbic acid 40 mg/kg prior to Tolbutamide administration (20 mg/kg).
Administration: Oral administration
Result: L-ascorbic acid (40 mg/kg alone) produced 42.53% blood glucose reduction at 1.5 h and Tolbutamide 20 mg/kg produced 45.09 at 4 h. Administration of L-ascorbic acid 40 mg/kg body weight prior to Tolbutamide produced antidiabetic activity at 0.5 h and was maintained for 6 h.
Masse moléculaire

176.12

Formule

C6H8O6
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

OC([C@@]1(11)[C@H](CO)O)=C(O)C(O1)=O
Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

RT, protect from light

In solvent -80°C 1 year
-20°C 6 months
Solvant et solubilité
In Vitro: 

H2O : ≥ 100 mg/mL (567.79 mM)

DMSO : 100 mg/mL (567.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 5.6779 mL 28.3897 mL 56.7795 mL
5 mM 1.1356 mL 5.6779 mL 11.3559 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 5 mg/mL (28.39 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 5 mg/mL (28.39 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (567.79 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Pureté et documentation
Références

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT
100-01-10UG
RH BDNF
 10UG 
100-01-100UG
RH BDNF
 100UG